MENVEO (meningococcal Group A, C, W-135 and Y conjugate vaccine) - Invasive meningococcal group A, C, W-135
Reason for request
Summary of opinion
Favourable opinion in the active immunisation of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease.
No clinical added value of the new forms compared to the forms already available.
Clinical Benefit
| Substantial |
The clinical benefit of MENVEO (meningococcal Group A, C, W-135 and Y conjugate vaccine) solution for injection is substantial in the active immunisation of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease. The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that provides no clinical added value (CAV V) compared to the forms already listed. |
